Wegovy is Novo Nordisk's branded semaglutide for chronic weight management. The injectable form launched in 2021. Oral Wegovy — a reformulated, higher-dose oral semaglutide — launched in late 2025 and early 2026, with the 1.5mg starter dose at $149/month and the 4mg dose moving from $149 to $199 effective April 15, 2026.
The most cited Wegovy data: SELECT (20% MACE reduction in non-diabetic adults with obesity), the STEP series for weight loss, and recent comparative work suggesting oral Wegovy may edge ahead of Foundayo (orforglipron) on weight loss despite Foundayo's HbA1c lead. Wegovy is on the FDA's April 30 proposal to exclude semaglutide from the 503B bulks list — the compounded-Wegovy market has been a core revenue threat for Novo.
Stories here cover pricing, head-to-head readouts, payer coverage, and the compounding economics.
Real-world evidence for Wegovy (semaglutide 2.4 mg once weekly subcutaneous injection) documents 5.9% to 12% mean body weight reduction at 6 to 12 months across registry and claims analyses. This compares to 14.9% weight loss in the STEP-1 registrational trial that supported the FDA approval. The gap is primarily adherence-driven: missed doses, titration pauses, insurance-driven dose changes, and stop-restart cycles flatten real-world curves relative to the tight-adherence STEP-1 population. Cleveland Clinic research confirmed that injectable obesity medications produce smaller weight loss in a real-world setting compared to randomized clinical trials, with the gap larger in patient subgroups facing financial barriers to consistent supply. A large real-world study of nearly 8,000 patients who discontinued GLP-1 therapy found that most manage to keep the weight off or continue losing by restarting treatment, switching medications (typically to tirzepatide or higher-dose Wegovy), or adopting lifestyle changes. Patient satisfaction is driven primarily by perceived effectiveness rather than tolerability: effective weight loss even with gastrointestinal side effects is associated with continued treatment adherence, while lower-efficacy responses lead to early discontinuation regardless of tolerability. The real-world evidence has implications for retatrutide's likely commercial trajectory: the 28.7% Phase 3 ceiling may translate to 15-20% in real-world use depending on adherence patterns, which is still substantially above semaglutide's real-world 5.9-12% range.
The higher-dose Wegovy 7.2 mg (semaglutide 7.2 mg once weekly subcutaneous injection, up from the current 2.4 mg maximum approved dose) is currently under FDA review for the adult obesity indication. The submission is based on the Phase 3 STEP UP trial that documented approximately 19% weight loss at the 7.2 mg dose over 68 weeks, versus approximately 15% weight loss for the currently-approved 2.4 mg dose (based on STEP 1 registrational data). The higher-dose submission provides Novo Nordisk with a line-extension option to defend the Wegovy franchise economics against the Eli Lilly tirzepatide franchise (Zepbound and Mounjaro), which continues to outperform on weight loss (approximately 21% at the 15 mg weekly dose per SURMOUNT-1). The Wegovy 7.2 mg efficacy also lags the Lilly retatrutide triple-agonist Phase 3 TRIUMPH-4 data that documented 28.7% mean body weight reduction at the 12 mg dose (the highest weight-loss magnitude in any Phase 3 obesity trial to date). Novo Nordisk's line-extension strategy is under scrutiny following the CagriSema REDEFINE 4 head-to-head miss versus tirzepatide (23.0% vs 25.5% treatment-policy estimand at 84 weeks). FDA decision timing on Wegovy 7.2 mg has not been publicly disclosed.
Novo Nordisk reported Q2 2026 earnings Tuesday August 4, 2026 with sales of 78.49 billion Danish kroner ($12.09 billion, +3% constant currency, +7% adjusted). Franchise performance: Wegovy injectable reached 19.484 billion DKK (+1% year-over-year); Wegovy pill (oral semaglutide 25/50 mg for obesity, launched Q1 2026) generated 3.218 billion DKK on more than 5 million cumulative prescriptions since launch; Ozempic (semaglutide for type 2 diabetes) grew 3% to 31.375 billion DKK. Novo Nordisk hiked its 2026 adjusted sales guidance to down 6% to flat at constant exchange rates, an improvement from the previous guidance that had reflected the substantially compressed pricing environment from the Trump administration Most-Favored-Nation deals and the July 1 Medicare GLP-1 Bridge Program launch. The Wegovy pill launch trajectory (5 million prescriptions in roughly six months) is one of the fastest oral obesity-drug uptake curves on record and effectively confirms the strength of the SNAC-enhanced oral peptide formulation strategy that Novo has pursued since the 2019 Rybelsus approval for type 2 diabetes. Novo shares tanked despite the raised outlook, reflecting concern about the tough Q2 2025 comparison and margin trajectory into 2027.
A CROI 2026 (Conference on Retroviruses and Opportunistic Infections) analysis presented earlier in 2026 documented that GLP-1 weight-loss medications generally work well for people living with HIV who are stable on antiretroviral therapy. Beyond the known obesity and type 2 diabetes benefits, the CROI analysis reported potential improvements in liver, gut, and cardiovascular health, plus reduced smoking rates in the HIV population on GLP-1 therapy. Real-world analysis of people living with HIV prescribed semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound) documented comparable weight loss to general-population Phase 3 trial data with no new safety signals specific to the HIV population. Approximately 40% of people living with HIV in the US also have obesity, and cardiovascular disease is one of the primary drivers of morbidity and mortality in the HIV-treated population. The CROI analysis supports GLP-1 therapy as a reasonable consideration in HIV patients with obesity or metabolic-syndrome comorbidities, particularly following the AIDS 2026 conference programming that concluded Friday July 31 in Rio de Janeiro emphasizing the sustained management of HIV alongside comorbid conditions in the current global funding-constrained environment. The finding also intersects with the ongoing peptide-adjacent HIV therapeutic landscape covered by the July 2026 Gilead-Merck ISLEND-1 and ISLEND-2 once-weekly islatravir/lenacapavir data and the Merck alimatravir monthly HIV prevention pill.
Q2 2026 earnings from the peptide-and-obesity big three arrive next week. Merck (NYSE: MRK) reports Tuesday August 4 before market open with analyst consensus at $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025), reflecting post-Keytruda loss-of-exclusivity strategic repositioning and LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor approved July 16, 2026) launch costs. Eli Lilly (NYSE: LLY) reports Wednesday August 5 before market open with analyst consensus at $20.26 billion revenue and $6.71 EPS. Prediction markets put a 70% probability on another Lilly earnings beat, 96.4% odds Mounjaro (tirzepatide) clears $7.5 billion Q2, 87% odds Zepbound (tirzepatide) tops $4 billion Q2, and Foundayo (orforglipron, oral small-molecule GLP-1) weekly prescriptions near 20,000 as the primary analyst focus number after the April 2026 FDA approval. Novo Nordisk reports Wednesday August 5 H1 2026 results (Novo reports half-year rather than quarterly), with Wegovy pill (oral semaglutide 25/50 mg) Q1 2026 sales of approximately $354 million providing the H1 baseline. The three earnings prints together will frame second-half 2026 obesity market trajectory and the competitive positioning across incretin, macrocyclic peptide, and small-molecule oral GLP-1 franchises.
The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.
Australia's Therapeutics Goods Administration (TGA) issued a class-wide product warning update Saturday July 25, 2026 for GLP-1 receptor agonists on non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe form of eye disorder that may result in permanent visual impairment including blindness. No treatment has been shown to improve visual acuity outcomes after NAION onset. The label update applies across all five GLP-1 RA products currently marketed in Australia: Trulicity (dulaglutide, Eli Lilly), Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly), and Saxenda (liraglutide, Novo Nordisk). The Advisory Committee on Medicines concluded that the current evidence supports the signal for semaglutide but not for dulaglutide or tirzepatide. A search of the Australian Database of Adverse Event Notifications (DAEN) found 36 cases of optic ischaemic neuropathy with GLP-1 RAs, including 23 for semaglutide, 10 for tirzepatide, and 3 for liraglutide. Patient guidance advises seeking urgent medical attention for any sudden vision loss including partial loss of vision. The Australian action follows the UK MHRA Drug Safety Update on semaglutide and NAION issued February 5, 2026.
Novo Nordisk announced Friday July 24, 2026 that it has filed for a temporary restraining order (TRO) and preliminary injunction in the US District Court for the District of New Jersey to immediately block Eli Lilly's national Zepbound (tirzepatide) and Mounjaro (tirzepatide) direct-to-consumer advertising campaigns. The escalation comes three business days after Novo's original complaint filed Tuesday July 21 alleging that Lilly's ads rely on outdated Wegovy (semaglutide) dose comparisons that do not account for the newer, higher-dose FDA-approved semaglutide options currently available. Through the TRO and preliminary injunction motions, Novo Nordisk seeks immediate court-ordered removal of the disputed Lilly campaigns pending a full merits ruling on the underlying deceptive-advertising claims. Novo also seeks a permanent injunction requiring Lilly to pull all misleading comparative advertising across platforms and to conduct a corrective advertising campaign. The GLP-1 ad war has moved from network TV pharmacy-facing PBM negotiation into full federal court litigation for the first time in the class's US commercialization history. Court hearing dates on the TRO/preliminary injunction have not yet been reported publicly.
Novo Nordisk (NYSE: NVO) filed a federal lawsuit Tuesday July 21, 2026 against Eli Lilly (NYSE: LLY) alleging that Lilly has run 'deceptive' advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro (both tirzepatide), per STAT News reporting. The Novo complaint reportedly targets marketing claims that make Lilly's tirzepatide franchise appear more effective than the underlying clinical data support relative to Novo's Wegovy and Ozempic (both semaglutide). The lawsuit arrives against a competitive backdrop where Lilly has been extending its US commercial lead in the obesity market: Q1 2026 sales showed Mounjaro at $8.7 billion (up 125% year-over-year) and Zepbound at $4.2 billion (up 80%), while Novo Nordisk faced flat-to-declining semaglutide revenue after March 2026 price cuts, and Lilly overtook Novo in US GLP-1 market share. The SURMOUNT-5 head-to-head Phase 3 trial published earlier in 2026 showed superior efficacy for tirzepatide over semaglutide on weight loss endpoints; Novo's complaint appears to focus on how Lilly extrapolates the SURMOUNT-5 comparative data into consumer-facing advertising. The dispute frames the GLP-1 marketing battlefield ahead of Q2 earnings reports (Lilly August 5, Novo August 6).
STAT News published a major investigation Monday July 20, 2026 reporting that LifeMD, a US telehealth company promoted by Novo Nordisk as a partner for Wegovy and Ozempic access, has pushed clinicians to see more patients and dispense GLP-1 prescriptions more rapidly while providing what former workers describe as minimal screening and follow-up. Five former employees and two lawsuits filed by former top leaders allege that providers at LifeMD were pressed to review up to 25 patient cases per hour based only on the electronic intake forms patients themselves filled out, translating to approximately two minutes per case. Novo Nordisk currently lists LifeMD on its website as a partner that offers 'legitimate medicine sourcing and patient support' for people seeking GLP-1 drugs. LifeMD strenuously denies the allegations. The reporting extends the June-July concern set documented by the JAMA secret-shopper study (45 of 49 online sellers wrote semaglutide or tirzepatide prescriptions within a day with limited clinical oversight, July 7 digest coverage) and complements the peptide-telehealth-landscape reporting the site has tracked through 2026. The LifeMD story sits within the sprawling loosely-regulated GLP-1 telehealth industry that experts say has been boosted by Novo Nordisk and Eli Lilly as branded-drug demand expanded through 2025 and 2026.
CNBC Healthy Returns and the Peterson Health Technology Institute (PHTI) documented Wednesday July 8, 2026 that employer coverage of GLP-1 drugs for obesity has held steady at 36% year-over-year despite the Medicare GLP-1 Bridge launching on July 1 and putting downward pressure on the payer landscape. Mercer survey data shows 60% of employers cover GLP-1s for diabetes only, 36% cover for both diabetes and weight loss, 3% don't cover them at all, and 2% are not sure. Rather than expanding coverage, employers pursued alternative approaches: 27% steer workers to direct-to-consumer cash platforms (such as LillyDirect, NovoCare Pharmacy, and telehealth intermediaries), while 21% push workers to use FSA, HSA, or integrated HRA dollars. GoodRx data show the uninsured share for Zepbound rose 18% year-over-year, leaving over 114 million Americans with no commercial coverage for the drug; 88% of those who do have coverage face additional requirements like prior authorization. GLP-1 drugs accounted for 11.4% of annual claims for employers covering them in 2026, up from 6.9% in 2023, sustaining the affordability tension that has kept coverage stuck.
Gallup released Tuesday July 7, 2026 poll results (survey conducted May-June 2026 with 5,000+ respondents across all 50 states and DC) showing 1 in 9 US adults (11%) now take a GLP-1 medication for weight loss. That share tripled from 3% in the 2024 survey and rose from 8% in 2025. The US adult obesity rate, which peaked at 39.9% in 2022, has drifted down to 36.4% in 2026, a statistically significant decline that inversely tracks the rise in GLP-1 use. Awareness of GLP-1 drugs for weight loss climbed from 80% in 2024 to 91% in 2026. Diagnosis of diabetes held steady after 15 years of slow increase in prior surveys. Follow-up coverage ran through Wednesday-Friday (Foreign Policy Journal, Forbes' Zachary Folk, Medscape, Fox 7 Austin, Bakery & Snacks) framing the results as the first large-population evidence that GLP-1 uptake is bending the US obesity curve. Payer analyst commentary tracked in parallel: employers continue steering workers toward cash-pay GLP-1 platforms as sticker prices stay high and adherence remains a concern (roughly two-thirds of non-T2D GLP-1 patients discontinue within one year).
Novo Nordisk US Operations EVP Jamey Millar released a formal statement Wednesday July 1, 2026, framing the Medicare GLP-1 Bridge as 'an important step in getting Wegovy to more patients' and committing to continued work with CMS, healthcare professionals, pharmacists, and patient advocates on Bridge implementation. Millar's cardiovascular-outcome framing was the piece of the statement designed to distinguish Wegovy from competitor GLP-1s under the Bridge: 'Obesity is a serious, common chronic disease facing older Americans, and Wegovy is the only weight management medicine proven to reduce the risk of heart attack, stroke, or cardiovascular death in patients who also have known heart disease. That distinction matters for seniors age 65 and older, who have a high burden of both conditions.' The SELECT trial data (2023-2024) underpin the cardiovascular claim. The Bridge covers all doses and formulations of Wegovy injection (including the 7.2 mg Wegovy HD launched April 2026) and Wegovy pill (1.5, 4, 9, and 25 mg oral tablets, launched January 5, 2026 and reaching 3 million prescriptions by June 7). The program is available nationwide across all US states and territories through December 31, 2027. PharmExec and PR Newswire ran the announcement.
The Centers for Medicare and Medicaid Services' Medicare GLP-1 Bridge demonstration program launched Wednesday July 1, 2026, opening prior-authorization submissions through Humana as central processor and activating the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR). The program provides eligible Medicare Part D beneficiaries with $50/month access to four FDA-approved obesity drugs: Foundayo (orforglipron oral tablets, Eli Lilly), Wegovy injection (semaglutide, Novo Nordisk), Wegovy tablets (oral semaglutide in 1.5, 4, 9, and 25 mg strengths), and Zepbound KwikPen (tirzepatide single-dose autoinjector, Eli Lilly). CMS targets 72-hour prior-authorization turnaround. The Bridge runs through December 31, 2027 and transitions to the broader BALANCE Model launching January 2027 in Part D. It represents the first time Medicare has helped pay for drugs prescribed solely for obesity, breaking the 2003 Medicare Modernization Act exclusion that had barred obesity-only prescriptions from Part D coverage.
The Medicare GLP-1 Bridge demonstration program launches Wednesday July 1, 2026 (one day from this digest), providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound KwikPen through December 31, 2027. Operationally, Humana opens its central-processor function for prior-authorization submissions and claims adjudication starting tomorrow; the Bridge-specific pharmacy billing identifiers (BIN 028918, PCN MEDDGLP1BR) become active for first fills. Walgreens published pharmacist-navigation guidance Tuesday flagging that store pharmacists will help Medicare patients verify eligibility (the three-tier BMI-and-comorbidity criteria walked through in this site's June 29 patient-guide insight), confirm Part D enrollment status, and submit the Bridge prior-authorization request to Humana through the dedicated workflow. CNN published a June 29 consumer explainer flagging that the program is the first time Medicare has paid for drugs prescribed solely for obesity. The Bridge runs in parallel with the broader BALANCE Model launching January 2027 in Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE.
The Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge demonstration launches Wednesday July 1, 2026, five days from this digest's publication, providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen) for chronic weight management through December 31, 2027. Humana is the single central processor for prior authorization, claims adjudication, and pharmacy payment, operating outside of the standard Part D benefit's coverage and payment flow (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge). Two procedural details for prescribers: Medicare enrollment is not required to write a prescription or submit a prior-authorization request under the Bridge (the provider just cannot be on the Preclusion List), and prior-authorization requests will not be accepted or processed before July 1, when the prior-authorization form will be updated to include the fax submission number. Eligibility runs through three BMI tiers: BMI ≥35 with no additional requirement; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease. The Bridge bridges to the broader BALANCE Model launching January 2027 in Medicare Part D.
Japan's Ministry of Health, Labour and Welfare granted Novo Nordisk a partial change approval of the manufacturing and marketing authorization for Wegovy (semaglutide) subcutaneous injection on June 19, 2026, adding an indication for metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis in patients with moderate to advanced fibrosis (stage F2 or F3). Wegovy is now the first approved MASH treatment in Japan. The approval is based on Part 1 of the global Phase 3 ESSENCE study where semaglutide 2.4 mg demonstrated statistically significant superiority to placebo on the co-primary endpoints of liver fibrosis improvement without worsening of MASH, and MASH resolution without worsening of fibrosis. Wegovy is co-promoted in Japan by Novo Nordisk Pharma and Sumitomo Pharma under the October 2025 co-promotion agreement. This is the second major MASH regulatory milestone for semaglutide after the FDA's August 2025 approval.
Wegovy and Mounjaro became reimbursable by French Health Insurance effective June 15, 2026 under orders published in the May 28, 2026 Journal Officiel. The patient co-payment rate is 35%, leaving 65% public coverage by the Sécurité Sociale. Eligibility is restricted to specific patient profiles: adults with BMI ≥30 plus a major obesity-associated comorbidity (Wegovy) or with type 2 diabetes (Mounjaro). The decision follows the UK and Switzerland in extending public insurance to GLP-1 obesity therapy, and marks a paradigm shift from 'personal responsibility' toward 'treatable disease' framing in continental European health systems. The change comes ahead of EMA Wegovy pill (oral semaglutide 25 mg) EU launches in H2 2026 following the May 22 CHMP positive opinion.